XTX Topco’s ProQR Therapeutics PRQR Stock Holding History

XTX Topco’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$125K	Sell	77,287 -40,613	-34%	-$66.6K	﹤0.01%	3023
2025 Q4	$238K	Buy	117,900 +107,713	+1,057%	+$252K	0.01%	2266
2025 Q3	$21.7K	Buy	+10,187	New	+$22.3K	﹤0.01%	2316
2025 Q2	–	Sell	-16,079	Closed	-$21.4K	–	2999
2025 Q1	$21.4K	Sell	16,079 -45,518	-74%	-$96.9K	﹤0.01%	2128
2024 Q4	$163K	Buy	+61,597	New	+$196K	0.01%	1632
2023 Q3	–	Sell	-16,405	Closed	-$26.6K	–	1923
2023 Q2	$26.6K	Buy	16,405 +6,245	+61%	+$12.2K	﹤0.01%	1298
2023 Q1	$21.6K	Buy	+10,160	New	+$31.1K	﹤0.01%	1209
2022 Q2	–	Sell	-210,587	Closed	-$191K	–	1060
2022 Q1	$191K	Buy	+210,587	New	+$705K	0.08%	427

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

XTX Topco's PRQR Position: Q1 2026 in Review

XTX Topco reduced its ProQR Therapeutics (PRQR) stake by 34% in Q1 2026, selling an estimated $66.6K and leaving 77,287 shares worth $125K. The position accounts for ﹤0.01% of the portfolio, ranked #3023.

XTX Topco first reported a position in PRQR in Q1 2022 and has held it in 8 quarters since. The position peaked at $238K in Q4 2025. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

XTX Topco held 77,287 shares of ProQR Therapeutics worth $125K as of Q1 2026.
XTX Topco sold 40,613 ProQR Therapeutics shares in Q1 2026, an estimated $66.6K.
ProQR Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q1 2026, its #3023 holding.
XTX Topco first reported a position in ProQR Therapeutics in Q1 2022 and has held it in 8 quarters since.
XTX Topco's ProQR Therapeutics position peaked at $238K in Q4 2025.
69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.